Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 5
2019 6
2020 4
2021 4
2022 5
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Hata A, et al. J Clin Oncol. 2022 Jan 10;40(2):180-188. doi: 10.1200/JCO.21.01315. Epub 2021 Nov 18. J Clin Oncol. 2022. PMID: 34793245 Free PMC article. Clinical Trial.
PURPOSE: We evaluated the efficacy and safety of fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) for preventing highly emetogenic chemotherapy-induced nausea and vomiting. ...
PURPOSE: We evaluated the efficacy and safety of fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) for preventing highly emetogeni …
A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC.
Matsuura K, Tsurutani J, Inoue K, Tanabe Y, Taira T, Kubota K, Tamura T, Saeki T. Matsuura K, et al. Cancer. 2022 Apr 15;128(8):1692-1698. doi: 10.1002/cncr.34088. Epub 2022 Jan 19. Cancer. 2022. PMID: 35045185 Free PMC article. Clinical Trial.
BACKGROUND: Fosnetupitant (FosNTP), an intravenous neurokinin 1 receptor antagonist, demonstrated a favorable safety profile with a potentially low risk of injection site reactions (ISRs) and promising antiemetic efficacy in patients receiving cisplatin-based highly emetog …
BACKGROUND: Fosnetupitant (FosNTP), an intravenous neurokinin 1 receptor antagonist, demonstrated a favorable safety profile with a p …
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Shirley M. Shirley M. Drugs. 2021 Jul;81(11):1331-1342. doi: 10.1007/s40265-021-01558-2. Epub 2021 Jul 22. Drugs. 2021. PMID: 34292534 Free PMC article. Review.
Netupitant/palonosetron (NEPA; Akynzeo()), available in oral and intravenous (IV) formulations, is a fixed-dose combination of the neurokinin 1 (NK1) receptor antagonist netupitant (or the prodrug, fosnetupitant, in the IV formulation) and the second-generation serotonin 3 …
Netupitant/palonosetron (NEPA; Akynzeo()), available in oral and intravenous (IV) formulations, is a fixed-dose combination of the neurokini …
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).
Hata A, Shiraishi Y, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Hata A, et al. Oncol Ther. 2022 Jun;10(1):253-262. doi: 10.1007/s40487-022-00188-2. Epub 2022 Mar 4. Oncol Ther. 2022. PMID: 35246827 Free PMC article.
METHODS: Patients scheduled to receive cisplatin-based chemotherapy were randomized 1:1 to fosnetupitant 235 mg or fosaprepitant 150 mg in combination with PALO 0.75 mg and DEX. ...CONCLUSION: In this exploratory analysis, fosnetupitant appeared to be more effective …
METHODS: Patients scheduled to receive cisplatin-based chemotherapy were randomized 1:1 to fosnetupitant 235 mg or fosaprepitant 150 …
Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.
Tyler T, Schultz A, Venturini A, Giuliano C, Bernareggi A, Spezia R, Voisin D, Stella V. Tyler T, et al. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1405-1418. doi: 10.1002/cpdd.1183. Epub 2022 Oct 20. Clin Pharmacol Drug Dev. 2022. PMID: 36263927 Clinical Trial.
In this phase 1 study, subjects received a 30-minute placebo or fosnetupitant (17.6-353 mg) infusion and an oral NEPA or placebo capsule, with 2-sequence crossover treatment for fosnetupitant 118- to 353-mg dose cohorts. ...The most common treatment-related AEs were …
In this phase 1 study, subjects received a 30-minute placebo or fosnetupitant (17.6-353 mg) infusion and an oral NEPA or placebo caps …
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V, Adams A, Haque M, Scheckel B, Kreuzberger N, Monsef I, Jordan K, Kuhr K, Skoetz N. Piechotta V, et al. Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2. Cochrane Database Syst Rev. 2021. PMID: 34784425 Free PMC article. Review.
Evidence from NMA (39 RCTs, 21,642 participants; 12 treatment combinations with NK1 and 5-HT3 inhibitors) suggests that the following drug combinations are more efficacious than aprepitant + granisetron for completely controlling vomiting during the overall treatment phase (one t …
Evidence from NMA (39 RCTs, 21,642 participants; 12 treatment combinations with NK1 and 5-HT3 inhibitors) suggests that the following drug c …
Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Sugawara S, Inui N, Kanehara M, Morise M, Yoshimori K, Kumagai T, Fukui T, Minato K, Iwashima A, Takeda Y, Kubota K, Saeki T, Tamura T. Sugawara S, et al. Cancer. 2019 Nov 15;125(22):4076-4083. doi: 10.1002/cncr.32429. Epub 2019 Aug 5. Cancer. 2019. PMID: 31381152 Free PMC article. Clinical Trial.
Of these, 194 patients, 195 patients, and 195 patients, respectively, in the placebo and fosnetupitant 81-mg and 235-mg dose groups were evaluable for efficacy. The overall CR rate was 54.7% for the placebo group, 63.8% for the fosnetupitant 81-mg dose group (adjust …
Of these, 194 patients, 195 patients, and 195 patients, respectively, in the placebo and fosnetupitant 81-mg and 235-mg dose groups w …
Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Kurteva G, Chilingirova N, Rizzi G, Caccia T, Stella V, Bernareggi A. Kurteva G, et al. Eur J Pharm Sci. 2019 Nov 1;139:105041. doi: 10.1016/j.ejps.2019.105041. Epub 2019 Aug 9. Eur J Pharm Sci. 2019. PMID: 31404621 Clinical Trial.
Twenty-four patients received the complete i.v. NEPA infusion volume. Fosnetupitant maximum plasma concentration (C(max)) was reached at the end of infusion and decreased to <1% of C(max) 30 min later. Netupitant was rapidly released from its prodrug and C(max) of 590 n …
Twenty-four patients received the complete i.v. NEPA infusion volume. Fosnetupitant maximum plasma concentration (C(max)) was reached …
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi G, Navari R, Gralla RJ, Karthaus M. Schwartzberg L, et al. Ann Oncol. 2018 Jul 1;29(7):1535-1540. doi: 10.1093/annonc/mdy169. Ann Oncol. 2018. PMID: 29722791 Free article. Clinical Trial.
An intravenous (i.v.) formulation of the NEPA combination (fosnetupitant 235 mg plus PALO 0.25 mg) has been developed. PATIENTS AND METHODS: This randomized, multinational, double-blind, stratified (by sex and country) phase III study (NCT02517021) in chemotherapy-naive pa …
An intravenous (i.v.) formulation of the NEPA combination (fosnetupitant 235 mg plus PALO 0.25 mg) has been developed. PATIENTS AND M …
Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
Aapro M, Jordan K, Scotté F, Celio L, Karthaus M, Roeland E. Aapro M, et al. Curr Cancer Drug Targets. 2022;22(10):806-824. doi: 10.2174/1568009622666220513094352. Curr Cancer Drug Targets. 2022. PMID: 35570542 Free PMC article. Review.
NEPA is the first and only fixed combination antiemetic, composed of netupitant (oral)/fosnetupitant (intravenous) and palonosetron, which, together with dexamethasone, constitute a triple antiemetic combination recommended for the prevention of CINV for patients receiving …
NEPA is the first and only fixed combination antiemetic, composed of netupitant (oral)/fosnetupitant (intravenous) and palonosetron, …
21 results